Mouse Anti-Human VEGF-A

Slide this table

Cat-Nr.101-M56
Size100 µg
Price255 €
CategoryMonoclonal Antibody
Clone Nr.(#3C5)
IsotypeIgG1
Species ReactivityHuman
Formulationlyophilized
BufferPBS
ReconstitutionCentrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
Stability and StorageThe lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.
PreparationThe monoclonal antibody was produced with the help of BALB/c mice using recombinant human VEGF165 (45 kDa) as the immunizing antigen. Mouse IgG1 antibody (clone 3C5) from hybridomas was purified from cell culture supernatant by Protein G chromatography.
Antigenrecombinant human VEGF165 (RT# 300-036)
ApplicationELISA, WB
SynonymsVEGFA; VPF; VEGF; MVCD1
DescriptionVascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.
Uniprot IDP15692
Protein RefSeqNP_001165097
mRNA RefSeqNM_001171626

Figures


Reference

  1. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. A. Bergmann et al., J Cell Mol Med. 2010 Jun; 14(6b): 1857–1867.

All prices plus VAT + possible delivery charges